Cargando…

Comorbidities in interstitial lung diseases

Fibrosing lung disorders include a large number of diseases with diverse behaviour. Patients can die because of the progression of their illness, remain stable or even improve after appropriate treatment has been instituted. Comorbidities, such as acute and chronic infection, gastro-oesophageal refl...

Descripción completa

Detalles Bibliográficos
Autores principales: Margaritopoulos, George A., Antoniou, Katerina M., Wells, Athol U.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488735/
https://www.ncbi.nlm.nih.gov/pubmed/28049126
http://dx.doi.org/10.1183/16000617.0027-2016
_version_ 1784792724852965376
author Margaritopoulos, George A.
Antoniou, Katerina M.
Wells, Athol U.
author_facet Margaritopoulos, George A.
Antoniou, Katerina M.
Wells, Athol U.
author_sort Margaritopoulos, George A.
collection PubMed
description Fibrosing lung disorders include a large number of diseases with diverse behaviour. Patients can die because of the progression of their illness, remain stable or even improve after appropriate treatment has been instituted. Comorbidities, such as acute and chronic infection, gastro-oesophageal reflux, pulmonary hypertension, lung cancer, cardiovascular diseases, and obstructive sleep apnoea, can pre-exist or develop at any time during the course of the disease and, if unidentified and untreated, may impair quality of life, impact upon the respiratory status of the patients, and ultimately lead to disease progression and death. Therefore, early identification and accurate treatment of comorbidities is essential.
format Online
Article
Text
id pubmed-9488735
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher European Respiratory Society
record_format MEDLINE/PubMed
spelling pubmed-94887352022-11-14 Comorbidities in interstitial lung diseases Margaritopoulos, George A. Antoniou, Katerina M. Wells, Athol U. Eur Respir Rev Reviews Fibrosing lung disorders include a large number of diseases with diverse behaviour. Patients can die because of the progression of their illness, remain stable or even improve after appropriate treatment has been instituted. Comorbidities, such as acute and chronic infection, gastro-oesophageal reflux, pulmonary hypertension, lung cancer, cardiovascular diseases, and obstructive sleep apnoea, can pre-exist or develop at any time during the course of the disease and, if unidentified and untreated, may impair quality of life, impact upon the respiratory status of the patients, and ultimately lead to disease progression and death. Therefore, early identification and accurate treatment of comorbidities is essential. European Respiratory Society 2017-01-03 /pmc/articles/PMC9488735/ /pubmed/28049126 http://dx.doi.org/10.1183/16000617.0027-2016 Text en Copyright ©ERS 2017. https://creativecommons.org/licenses/by-nc/4.0/ERR articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
spellingShingle Reviews
Margaritopoulos, George A.
Antoniou, Katerina M.
Wells, Athol U.
Comorbidities in interstitial lung diseases
title Comorbidities in interstitial lung diseases
title_full Comorbidities in interstitial lung diseases
title_fullStr Comorbidities in interstitial lung diseases
title_full_unstemmed Comorbidities in interstitial lung diseases
title_short Comorbidities in interstitial lung diseases
title_sort comorbidities in interstitial lung diseases
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488735/
https://www.ncbi.nlm.nih.gov/pubmed/28049126
http://dx.doi.org/10.1183/16000617.0027-2016
work_keys_str_mv AT margaritopoulosgeorgea comorbiditiesininterstitiallungdiseases
AT antonioukaterinam comorbiditiesininterstitiallungdiseases
AT wellsatholu comorbiditiesininterstitiallungdiseases